Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms

Khan, Mohid S., Kirkwood, Amy A., Tsigani, Theodora, Lowe, Helen, Goldstein, Robert, Hartley, John A., Caplin, Martyn E. and Meyer, Tim 2016. Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms. Clinical Cancer Research 22 (1) , 79–85. 10.1158/1078-0432.CCR-15-1008

Full text not available from this repository.

Abstract

Purpose: To investigate posttreatment circulating tumor cell (CTC) counts in patients with neuroendocrine neoplasms (NENs) as a predictive biomarker for disease progression and overall survival (OS). Experimental Design: Patients with metastatic NENs commencing therapy were prospectively recruited (n = 138). Blood samples were obtained for evaluation of CTCs using the CellSearch platform and for chromogranin A (CgA) at baseline, three to five (median, 4.3) weeks and 10 to 15 (median 13.7) weeks after commencing therapy. Radiologic response and OS data were collected. Results: There was a significant association between first posttreatment CTC count and progressive disease (PD; P < 0.001). Only 8% of patients with a favorable “CTC response” (0 CTCs at baseline and 0 at first posttreatment time-point; or ≥50% reduction from baseline) had PD compared with 60% in the unfavorable group (<50% reduction or increase). Changes in CTCs were strongly associated with OS (P < 0.001), the best prognostic group being patients with 0 CTCs before and after therapy; followed by those with ≥50% reduction in CTCs [hazard ratio (HR), 3.31]; with those with a <50% reduction or increase in CTCs (HR, 5.07) having the worst outcome. In multivariate analysis, changes in CTCs had the strongest association with OS (HR, 4.13; P = 0.0002). Changes in CgA were not significantly associated with survival. Conclusions: Changes in CTCs are associated with response to treatment and OS in metastatic NENs, suggesting CTCs may be useful as surrogate markers to direct clinical decision making. Clin Cancer Res; 22(1); 79–85. ©2015 AACR.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Publisher:	American Association for Cancer Research
ISSN:	1078-0432
Date of Acceptance:	28 June 2015
Last Modified:	12 Mar 2025 16:00
URI:	https://orca.cardiff.ac.uk/id/eprint/176564

Actions (repository staff only)

Edit Item